Ellen K. Wasan

3.5k total citations · 2 hit papers
50 papers, 2.8k citations indexed

About

Ellen K. Wasan is a scholar working on Molecular Biology, Pharmaceutical Science and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ellen K. Wasan has authored 50 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 12 papers in Pharmaceutical Science and 10 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ellen K. Wasan's work include RNA Interference and Gene Delivery (14 papers), Research on Leishmaniasis Studies (10 papers) and Advanced Drug Delivery Systems (9 papers). Ellen K. Wasan is often cited by papers focused on RNA Interference and Gene Delivery (14 papers), Research on Leishmaniasis Studies (10 papers) and Advanced Drug Delivery Systems (9 papers). Ellen K. Wasan collaborates with scholars based in Canada, United States and Sweden. Ellen K. Wasan's co-authors include Kishor M. Wasan, Marcel B. Bally, Pavel Gershkovich, Dorothy L. Reimer, Noorjahan Aibani, Parth Patel, Vincent Plassat, Ronak Savla, Jeff Browne and Ludger M. Ickenstein and has published in prestigious journals such as Advanced Drug Delivery Reviews, Journal of Controlled Release and The Journal of Infectious Diseases.

In The Last Decade

Ellen K. Wasan

50 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

2017 982 citations Kishor M. Wasan, Ellen K. Wasan et al. Pharmaceutics profile →
Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery

2021 229 citations Noorjahan Aibani, Parth Patel et al. Pharmaceutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ellen K. Wasan Canada	22	888	837	769	456	304	50	2.8k
Mohsen Tafaghodi Iran	33	720 0.8×	730 0.9×	810 1.1×	391 0.9×	175 0.6×	119	2.8k
Maria Manuela Gaspar Portugal	35	1.3k 1.5×	774 0.9×	467 0.6×	742 1.6×	147 0.5×	131	3.6k
Noémi Csaba Spain	30	1.1k 1.3×	797 1.0×	1.1k 1.5×	369 0.8×	146 0.5×	75	2.7k
Medha Joshi United States	19	1.3k 1.5×	480 0.6×	1.1k 1.4×	248 0.5×	239 0.8×	51	3.1k
Lucas Antônio Miranda Ferreira Brazil	33	729 0.8×	585 0.7×	740 1.0×	336 0.7×	457 1.5×	99	2.5k
Prabhat Ranjan Mishra India	34	1.3k 1.4×	891 1.1×	870 1.1×	581 1.3×	388 1.3×	126	3.5k
Didier Betbeder France	37	1.1k 1.2×	780 0.9×	612 0.8×	360 0.8×	90 0.3×	109	3.8k
Munira Momin India	24	924 1.0×	557 0.7×	500 0.7×	585 1.3×	165 0.5×	85	2.7k
Socorro Espuelas Spain	30	743 0.8×	598 0.7×	681 0.9×	256 0.6×	521 1.7×	85	2.5k

Countries citing papers authored by Ellen K. Wasan

Since Specialization

Citations

This map shows the geographic impact of Ellen K. Wasan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen K. Wasan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen K. Wasan more than expected).

Fields of papers citing papers by Ellen K. Wasan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen K. Wasan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen K. Wasan. The network helps show where Ellen K. Wasan may publish in the future.

Co-authorship network of co-authors of Ellen K. Wasan

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen K. Wasan. A scholar is included among the top collaborators of Ellen K. Wasan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen K. Wasan. Ellen K. Wasan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wasan, Ellen K., et al.. (2024). Chitosan non-particulate vaccine delivery systems. Journal of Pharmacy & Pharmaceutical Sciences. 27. 12921–12921. 5 indexed citations

Alwani, Saniya, Ellen K. Wasan, & Ildikó Badea. (2024). Solid Lipid Nanoparticles for Pulmonary Delivery of Biopharmaceuticals: A Review of Opportunities, Challenges, and Delivery Applications. Molecular Pharmaceutics. 21(7). 3084–3102. 17 indexed citations

Aibani, Noorjahan, Parth Patel, Rachelle Buchanan, et al.. (2022). Assessing the In Vivo Effectiveness of Cationic Lipid Nanoparticles with a Triple Adjuvant for Intranasal Vaccination against the Respiratory Pathogen Bordetella pertussis. Molecular Pharmaceutics. 19(6). 1814–1824. 7 indexed citations

Aibani, Noorjahan, et al.. (2021). Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery. Pharmaceutics. 13(10). 1686–1686. 229 indexed citations breakdown →

Wasan, Ellen K., et al.. (2019). Investigation into spinal anesthetic failure with hyperbaric bupivacaine: the role of cold exposure on bupivacaine degradation. Canadian Journal of Anesthesia/Journal canadien d anesthésie. 66(7). 803–812. 3 indexed citations

Cawthray, Jacqueline F., Ellen K. Wasan, & Kishor M. Wasan. (2017). Bone-seeking agents for the treatment of bone disorders. Drug Delivery and Translational Research. 7(4). 466–481. 19 indexed citations

Wasan, Ellen K., et al.. (2015). Lipid-lowering Activity of Natural and Semi-Synthetic Sterols and Stanols. Journal of Pharmacy & Pharmaceutical Sciences. 18(4). 344–344. 21 indexed citations

Wasan, Kishor M., Olena Sivak, Karen H. Bartlett, Ellen K. Wasan, & Pavel Gershkovich. (2014). Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature. Drug Development and Industrial Pharmacy. 41(9). 1425–1430. 10 indexed citations

Gershkovich, Pavel, et al.. (2012). Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. International Journal of Pharmaceutics. 436(1-2). 318–323. 9 indexed citations

10.

León, Carlos, Jinkyung Lee, Karen H. Bartlett, et al.. (2011). In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines. Lipids in Health and Disease. 10(1). 144–144. 13 indexed citations

11.

Wasan, Ellen K., Pavel Gershkovich, Jinying Zhao, et al.. (2010). A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model. PLoS neglected tropical diseases. 4(12). e913–e913. 46 indexed citations

12.

Ickenstein, Ludger M., Gigi Ngar Chee Chiu, Marcel B. Bally, et al.. (2009). The functional roles of poly(ethylene glycol)‐lipid and lysolipid in the drug retention and release from lysolipid‐containing thermosensitive liposomes in vitro and in vivo. Journal of Pharmaceutical Sciences. 99(5). 2295–2308. 96 indexed citations

13.

Gershkovich, Pavel, Ellen K. Wasan, Olena Sivak, et al.. (2009). Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. Journal of Antimicrobial Chemotherapy. 65(3). 535–537. 20 indexed citations

14.

Berger, Stuart A., et al.. (2006). A Parenteral Econazole Formulation Using a Novel Micelle-to-Liposome Transfer Method: In Vitro Characterization and Tumor Growth Delay in a Breast Cancer Xenograft Model. Pharmaceutical Research. 23(11). 2575–2585. 15 indexed citations

15.

Wasan, Ellen K., Dorothy L. Reimer, Pierrot Harvie, et al.. (2003). Targeted Gene Transfer: A Practical Guide Based on Experience with Lipid-Based Plasmid Delivery Systems. Humana Press eBooks. 25. 255–304. 1 indexed citations

16.

Wasan, Ellen K., Dawn Waterhouse, Olena Sivak, et al.. (2002). Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells. International Journal of Pharmaceutics. 241(1). 57–64. 9 indexed citations

17.

Reimer, Dorothy L., Spencer Kong, Myrna A. Monck, et al.. (1999). Liposomal Lipid and Plasmid DNA Delivery to B16/BL6 Tumors after Intraperitoneal Administration of Cationic Liposome DNA Aggregates. Journal of Pharmacology and Experimental Therapeutics. 289(2). 807–815. 22 indexed citations

18.

Wasan, Ellen K., Pierrot Harvie, Katarina Edwards, Göran Karlsson, & Marcel B. Bally. (1999). A multi-step lipid mixing assay to model structural changes in cationic lipoplexes used for in vitro transfection. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1461(1). 27–46. 36 indexed citations

19.

Wasan, Ellen K., Alysa Fairchild, & Marcel B. Bally. (1998). Cationic Liposome–Plasmid DNA Complexes Used for Gene Transfer Retain a Significant Trapped Volume. Journal of Pharmaceutical Sciences. 87(1). 9–14. 10 indexed citations

20.

Wasan, Ellen K., Dorothy L. Reimer, & Marcel B. Bally. (1996). Plasmid DNA is Protected against Ultrasonic Cavitation-Induced Damage when Complexed to Cationic Liposomes. Journal of Pharmaceutical Sciences. 85(4). 427–433. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact